Clovis Oncology (CLVS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Clovis Oncology Announces Second Quarter 2018 Operating Results
August 1, 2018 4:05 PM EDT$23.8M in Rubraca® sales for the second quarter of 2018 compared to $14.6M for Q2 2017 Rubraca approved in U.S. on April 6, 2018 for expanded ovarian cancer maintenance treatment indication Rubraca granted Marketing Authorization by European Commission on May 29 for treatment of recurrent ovarian cancer EMA validated EU application to include ovarian cancer maintenance treatment in the Rubraca Marketing Authorization; CHMP opinion anticipated by year-end 2018 Initial TRITON2 data to be presented at ESMO in October; first data presentation of Rubraca in metastatic castration-resistant... More
